Is Melanoma Overdiagnosed? What Rising Incidence and Flat Mortality Reveal

Melanoma diagnoses in the United States have risen roughly sixfold over the past four decades, yet the death rate barely moved for most of that period. That combination, a steep climb in new cases without a matching rise in mortality, is the classic epidemiologic fingerprint of overdiagnosis: the detection of cancers that satisfy the pathologic definition of melanoma but would never have caused symptoms or death in a person's lifetime. The evidence does not say melanoma is harmless or that early detection never helps. It says a large share of what we now count as melanoma, especially very thin and in situ lesions, likely represents indolent disease that treatment cannot improve because it was never going to progress.

The divergence that defines overdiagnosis

Overdiagnosis is not misdiagnosis. The pathology is real, and the lesion genuinely meets the criteria for melanoma. The problem is that some cancers grow so slowly, or not at all, that finding them confers no benefit and only exposes the patient to treatment. Epidemiologists infer overdiagnosis when incidence rises steeply while mortality stays flat, because a true increase in dangerous disease should eventually show up as more deaths.

An analysis by Kurtansky and colleagues in the Journal of Investigative Dermatology tracked United States data from 1975 to 2017 and found melanoma incidence rose about 459 percent. The most telling pattern appeared in women aged 55 to 74, where incidence climbed steadily while mortality stayed essentially flat, which the authors describe as the single clearest signature of overdiagnosis in the data.

The in situ surge

The pattern is sharpest for melanoma in situ, the earliest stage, confined to the epidermis. In that same analysis, in situ diagnoses rose roughly 4,675 percent, far outpacing the rise in invasive disease and still climbing at the end of the study period. When a category expands relentlessly yet almost no one in it dies of the disease, indolent detection is the most parsimonious explanation.

Why detection intensity matters

Rising incidence has an obvious candidate cause that has nothing to do with more cancer: more looking. In an analysis in the New England Journal of Medicine, Welch and colleagues reported that the share of fee-for-service Medicare beneficiaries undergoing a skin biopsy nearly doubled after 2004, and melanoma incidence in that population rose in parallel. More biopsies find more small lesions, and diagnostic thresholds have drifted, so that specimens once read as benign are now labeled melanoma. The authors argue that intensified skin examination is a more plausible driver of the rise than an undetected wave of lethal disease.

What complicates the story

The interpretation is not clean, and honest analysis has to hold two complications in view. First, melanoma mortality did finally begin falling after roughly 2013, largely because of genuinely effective new therapies for advanced disease. That decline reflects better treatment, not a reversal of overdiagnosis, and it can mask the incidence-mortality gap if read carelessly. Second, lead-time bias inflates survival statistics: diagnosing the same cancer earlier makes patients appear to live longer from the date of diagnosis even when the date of death is unchanged. Improved five-year survival is therefore weak evidence that early detection is saving lives, because both overdiagnosis and lead time push survival figures upward without moving mortality.

A natural experiment

One of the more elegant attempts to size the problem compared Black and White patients. Adamson, Suarez, and Welch reasoned in JAMA Dermatology that melanoma biology does not differ enough by race to explain divergent diagnosis trends, so incidence and mortality among Black patients, who are screened far less intensively, can serve as a proxy for the true change in disease burden. Melanoma incidence rose roughly sixfold in White men and about fourfold in White women from 1975 to 2014, but by less than 25 percent in Black patients over the same period. Using the Black trends as the counterfactual, the authors estimated that about 60 percent of melanomas in White men and 59 percent in White women diagnosed in 2014 represented overdiagnosis. Those figures carry wide confidence intervals, but their direction agrees with the incidence and mortality data.

What the screening evidence supports

If early detection reliably prevented death, whole-population screening would show a mortality benefit. It has not. In 2023 the United States Preventive Services Task Force again concluded that the evidence is insufficient to assess the balance of benefits and harms of visual skin examination to screen asymptomatic adults, an I statement, and found no reliable evidence that such screening lowers melanoma mortality at the population level. That is not a verdict that skin cancer is unimportant. It is an acknowledgment that population screening has never been shown to lower deaths, while its harms, including biopsies, scarring, cost, and anxiety, are real and common.

Reading the numbers without overcorrecting

None of this means thick or ulcerated melanomas are anything but dangerous, or that a changing, symptomatic lesion should be ignored. The overdiagnosis argument is narrow and specific: much of the growth in melanoma statistics comes from small, early, often in situ lesions whose detection has not translated into fewer deaths. Recognizing that helps explain why marketing which equates more skin checks with more lives saved outruns the evidence, and why pathologists and epidemiologists are working on ways to separate lesions that need treatment from those that never will. The honest position pairs uncertainty about which individual lesion is which with clarity that the aggregate curves point to substantial overdiagnosis.

This article is educational and not medical advice; decisions about a specific skin lesion or about screening should be made with a qualified clinician who knows your history.